Your browser doesn't support javascript.
loading
On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles.
Lukianova-Hleb, Ekaterina Y; Ren, Xiaoyang; Sawant, Rupa R; Wu, Xiangwei; Torchilin, Vladimir P; Lapotko, Dmitri O.
Afiliação
  • Lukianova-Hleb EY; Department of Biochemistry and Cell Biology, Rice University, Houston, Texas, USA.
  • Ren X; Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Sawant RR; Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts, USA.
  • Wu X; Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Torchilin VP; Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts, USA.
  • Lapotko DO; Department of Biochemistry and Cell Biology, Rice University, Houston, Texas, USA.
Nat Med ; 20(7): 778-784, 2014 Jul.
Article em En | MEDLINE | ID: mdl-24880615
Chemoradiation-resistant cancers limit treatment efficacy and safety. We show here the cancer cell-specific, on-demand intracellular amplification of chemotherapy and chemoradiation therapy via gold nanoparticle- and laser pulse-induced mechanical intracellular impact. Cancer aggressiveness promotes the clustering of drug nanocarriers and gold nanoparticles in cancer cells. This cluster, upon exposure to a laser pulse, generates a plasmonic nanobubble, the mechanical explosion that destroys the host cancer cell or ejects the drug into its cytoplasm by disrupting the liposome and endosome. The same cluster locally amplifies external X-rays. Intracellular synergy of the mechanical impact of plasmonic nanobubble, ejected drug and amplified X-rays improves the efficacy of standard chemoradiation in resistant and aggressive head and neck cancer by 100-fold in vitro and 17-fold in vivo, reduces the effective entry doses of drugs and X-rays to 2-6% of their clinical doses and efficiently spares normal cells. The developed quadrapeutics technology combines four clinically validated components and transforms a standard macrotherapy into an intracellular on-demand theranostic microtreatment with radically amplified therapeutic efficacy and specificity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Nanoestruturas / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Nanoestruturas / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2014 Tipo de documento: Article